Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FRTXNASDAQ:NLSPNASDAQ:PTIXNASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFRTXFresh Tracks Therapeutics$0.94-0.5%$0.92$0.03▼$1.03$5.59M0.542,709 shs2,402 shsNLSPNLS Pharmaceutics$1.49-3.2%$1.83$1.30▼$18.39$5.36M-0.3831,976 shs15,544 shsPTIXProtagenic Therapeutics$0.23-9.2%$0.30$0.18▼$1.87$1.64M0.43853,504 shs17.27 million shsSNGXSoligenix$2.21$2.33$1.83▼$14.92$5.55M2.03784,891 shs10,858 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFRTXFresh Tracks Therapeutics0.00%0.00%0.00%+25.08%+5.04%NLSPNLS Pharmaceutics-3.25%-3.25%-16.29%-31.65%+747.07%PTIXProtagenic Therapeutics-9.20%-13.69%-17.84%-56.30%-86.57%SNGXSoligenix0.00%-5.15%+0.45%-24.83%-74.42%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/AN/AN/APTIXProtagenic Therapeutics0.8693 of 5 stars0.03.00.00.02.21.70.6SNGXSoligenix1.523 of 5 stars0.05.00.00.02.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFRTXFresh Tracks Therapeutics 0.00N/AN/AN/ANLSPNLS Pharmaceutics 0.00N/AN/AN/APTIXProtagenic Therapeutics 0.00N/AN/AN/ASNGXSoligenix 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56NLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/APTIXProtagenic TherapeuticsN/AN/AN/AN/A$0.83 per shareN/ASNGXSoligenix$840K6.60N/AN/A$3.83 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/ANLSPNLS Pharmaceutics-$12.17MN/A0.00∞N/AN/AN/AN/A5/21/2025 (Estimated)PTIXProtagenic Therapeutics-$5M-$1.27N/A∞N/AN/A-308.97%-228.73%4/7/2025 (Estimated)SNGXSoligenix-$6.14M-$6.11N/AN/AN/A-1,473.38%-223.29%-74.18%5/9/2025 (Estimated)Latest PTIX, FRTX, SNGX, and NLSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024PTIXProtagenic TherapeuticsN/A-$0.24N/A-$0.24N/AN/A3/21/2025Full YearSNGXSoligenix-$0.95-$1.14-$0.19-$1.14$0.20 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/APTIXProtagenic TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFRTXFresh Tracks TherapeuticsN/AN/AN/ANLSPNLS PharmaceuticsN/A0.15N/APTIXProtagenic TherapeuticsN/A1.801.80SNGXSoligenixN/A2.282.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFRTXFresh Tracks Therapeutics25.04%NLSPNLS PharmaceuticsN/APTIXProtagenic Therapeutics7.97%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipFRTXFresh Tracks Therapeutics0.23%NLSPNLS Pharmaceutics16.40%PTIXProtagenic Therapeutics35.00%SNGXSoligenix2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableNLSPNLS Pharmaceutics63.60 million3.01 millionNot OptionablePTIXProtagenic Therapeutics27.24 million4.71 millionNot OptionableSNGXSoligenix202.51 million2.44 millionNot OptionablePTIX, FRTX, SNGX, and NLSP HeadlinesRecent News About These CompaniesAnalysts Issue Forecasts for Soligenix FY2025 EarningsMarch 30, 2025 | americanbankingnews.comQ1 Earnings Forecast for Soligenix Issued By Zacks Small CapMarch 29, 2025 | americanbankingnews.comSoligenix Reports Publication Describing Preclinical Efficacy Of CiVax - Quick FactsMarch 27, 2025 | nasdaq.comSoligenix selects IBN to spearhead corporate communicationsMarch 26, 2025 | markets.businessinsider.comSNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…March 26, 2025 | msn.comSoligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 26, 2025 | medindia.netIBN Initiates Coverage of Soligenix Inc.March 25, 2025 | globenewswire.comSoligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 25, 2025 | prnewswire.comSoligenix Trumps Year-End FinancialsMarch 21, 2025 | baystreet.caSoligenix Announces Recent Accomplishments and Year End 2024 Financial ResultsMarch 21, 2025 | prnewswire.comWhy Soligenix (NASDAQ: SNGX) Is ‘One to Watch’March 20, 2025 | theglobeandmail.comHyBryte™ Treatment Studies Presented at Two Medical Conferences in MarchMarch 6, 2025 | prnewswire.comSoligenix Aims To Push The Boundaries In Treating Rare DiseasesFebruary 26, 2025 | msn.comEQS-News: Soligenix Aims To Push The Boundaries In Treating Rare DiseasesFebruary 25, 2025 | markets.businessinsider.comSNGX: Presentation Highlights HyBryte Potential in CTCL…February 24, 2025 | msn.comEQS-News: Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's DiseaseFebruary 21, 2025 | finanzen.atEQS-News: Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026February 21, 2025 | markets.businessinsider.comSoligenix IncFebruary 18, 2025 | money.usnews.comSoligenix settles debt with Pontifax lendersFebruary 10, 2025 | msn.comSoligenix Repays Loan, Boosting Financial FlexibilityFebruary 10, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTIX, FRTX, SNGX, and NLSP Company DescriptionsFresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.NLS Pharmaceutics NASDAQ:NLSP$1.49 -0.05 (-3.25%) Closing price 04/2/2025 03:26 PM EasternExtended Trading$1.48 -0.01 (-0.60%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Protagenic Therapeutics NASDAQ:PTIX$0.23 -0.02 (-9.20%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.63 +0.41 (+178.85%) As of 05:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Soligenix NASDAQ:SNGX$2.21 0.00 (0.00%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$2.21 0.00 (0.00%) As of 04/2/2025 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
